DeGen Medical, Inc. ("DeGen") is a privately held medical device company headquartered at 1321-C North Cashua Drive, Florence, South Carolina. It was founded in 2011 and is led by CEO Craig Black. No public ticker or parent company is disclosed; third-party databases describe it as privately held with no reported venture funding, and size estimates vary widely (roughly 17–50 employees; revenue estimates of roughly $5–100 million depending on the source). Those figures are unverified estimates, not company-confirmed disclosures. (Sources: BioSpace company profile; CB Insights; company press releases.)
Products / operations. DeGen designs and manufactures spinal implant systems for complex spinal disorders, with an emphasis on patient-specific implants (PSIs). Its offerings include patient-specific interbody implants designed by a DeGen engineer working directly with the surgeon from CT, X-ray, or MRI imaging; off-the-shelf interbody implant systems; posterior fixation; and disc preparation instrumentation, marketed together as the Solar™ Platform, a 360° fusion solution. Manufacturing is in-house and additive, using a proprietary titanium material (Puri-Ti™), with a stated five-business-day lead time for patient-specific implants. The company also provides hospitals with clinical coding and DRG guidance. It states its designs are not AI- or machine-learning-generated. CB Insights lists roughly 26 patent filings, including an expandable intervertebral spacer patent.
Patent-litigation posture. DeGen is an operating company, not an NPE, and appears in the database solely as a defendant (0 plaintiff cases, 1 defendant case). This is consistent with a product manufacturer being sued rather than a party asserting an acquired portfolio.
Notable case. Carlsmed, Inc. v. DeGen Medical, Inc., filed September 15, 2026 in the U.S. District Court for the District of South Carolina, Florence Division — DeGen's home venue, not a plaintiff-friendly district such as the Eastern District of Texas. Carlsmed (Nasdaq: CARL), a publicly traded, AI-enabled personalized spine surgery company, asserts eight of its patents covering implants, methods, and systems and seeks injunctive relief and damages. The suit reflects direct competition in the personalized spine implant space.